The Effect of AMP Human Sodium Bicarbonate Lotion on Hydration

NCT04598386 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-10-14

No results posted yet for this study

Summary

The purpose of this research study is to evaluate the effects of a topical sodium bicarbonate lotion on physiological and psychological responses associated with hydration status and fluid balance in humans during passive heat stress. Currently, the ingestion of sodium has been an effective measure for improvements in fluid regulation and hydration status in humans. However, the investigators do not know its regulatory relationship with measurements of fluid balance when supplemented through the skin.

Conditions

  • Fluid Retention
  • Fluid Loss
  • Sodium Retention
  • Cognitive Change
  • Heat Exposure
  • Hyperhydration
  • Electrolyte and Fluid Balance Conditions

Interventions

OTHER

PR Lotion - AMP Human Performance

Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers \>2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.

OTHER

Placebo Lotion

Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.

Sponsors & Collaborators

  • AMP Human; Park City, UT

    collaborator UNKNOWN
  • United States Department of Defense

    collaborator FED
  • University of Connecticut

    lead OTHER

Principal Investigators

  • Douglas J Casa, PhD · Korey Stringer Institute - UConn

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-09
Primary Completion
2021-04-09
Completion
2021-04-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04598386 on ClinicalTrials.gov